Acelyrin, Inc. (SLRN)
NASDAQ: SLRN · IEX Real-Time Price · USD
6.68
+0.55 (8.97%)
Jul 16, 2024, 11:23 AM EDT - Market open

Company Description

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.

It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.

In addition, the company’s develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria.

Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Acelyrin, Inc.
Acelyrin logo
Country United States
Founded 2020
IPO Date May 5, 2023
Industry Biotechnology
Sector Healthcare
Employees 51
CEO Ms. Mina Kim

Contact Details

Address:
4149 Liberty Canyon Rd.
Agoura Hills, California 91301
United States
Phone 805-871-4300
Website acelyrin.com

Stock Details

Ticker Symbol SLRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001962918
CUSIP Number 00445A100
ISIN Number US00445A1007
Employer ID 85-2406735
SIC Code 2834

Key Executives

Name Position
Dr. Shao-Lee Lin M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Melanie Gloria B.S.N. Chief Operating Officer
Gilbert M. Labrucherie J.D. Chief Financial Officer, Principal Financial Officer and principal accounting officer
Mina Kim Chief Legal and Administrative Officer
Tyler Marciniak Head of Investor Relations and Communications
Ron Oyston Chief People Officer
Dr. Paul M. Peloso M.D., M.Sc. Chief Medical Officer
Suzy Buckhalter CPA Senior Director of Finance and Accounting
Kenneth A. Lock Chief Commercial Officer
Dr. Shephard Mpofu M.D. Senior Vice President of Development

Latest SEC Filings

Date Type Title
Jun 11, 2024 8-K Current Report
May 28, 2024 8-K/A [Amend] Current report
May 20, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 14, 2024 10-Q Quarterly Report
May 9, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 9, 2024 8-K Current Report
Apr 22, 2024 ARS Filing
Apr 22, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 22, 2024 DEF 14A Other definitive proxy statements
Apr 19, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals